Publication:
PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets

Date

2024-07-19

Authors

Blanco, Ester
Fernández-Rubio, Leticia
Garnica, Maider
García Granda, María Jesús
Bocanegra Gondán, Ana Isabel
Echaide Górriz, Míriam
Johnston, Colette
Edwards, Carolyn J.

Director

Publisher

EMBO Press
Acceso abierto / Sarbide irekia
Artículo / Artikulua
Versión publicada / Argitaratu den bertsioa

Project identifier

European Commission/Horizon 2020 Framework Programme/848166openaire
ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F00010/ES/recolecta
ISCIII//PI23%2F00196
ISCIII//COV20%2F00237
ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/ICI19%2F00069/ES/recolecta
Gobierno de Navarra//050-2019
Gobierno de Navarra//51-2021
Gobierno de Navarra//036-2023
Gobierno de Navarra//0011-1411-2020-000013
Gobierno de Navarra//0011-1411-2020-000033
Gobierno de Navarra//0011-1411-2019-000058
Métricas Alternativas

Abstract

Many cancer patients do not benefit from PD-L1/PD-1 blockade immunotherapies. PD-1 and LAG-3 co-upregulation in T-cells is one of the major mechanisms of resistance by establishing a highly dysfunctional state in T-cells. To identify shared features associated to PD-1/LAG-3 dysfunctionality in human cancers and T-cells, multiomic expression profiles were obtained for all TCGA cancers immune infiltrates. A PD-1/LAG-3 dysfunctional signature was found which regulated immune, metabolic, genetic, and epigenetic pathways, but especially a reinforced negative regulation of the TCR signalosome. These results were validated in T-cell lines with constitutively active PD-1, LAG-3 pathways and their combination. A differential analysis of the proteome of PD-1/LAG-3 T-cells showed a specific enrichment in ubiquitin ligases participating in E3 ubiquitination pathways. PD-1/LAG-3 co-blockade inhibited CBL-B expression, while the use of a bispecific drug in clinical development also repressed C-CBL expression, which reverted T-cell dysfunctionality in lung cancer patients resistant to PD-L1/PD-1 blockade. The combination of CBL-B-specific small molecule inhibitors with anti-PD-1/anti-LAG-3 immunotherapies demonstrated notable therapeutic efficacy in models of lung cancer refractory to immunotherapies, overcoming PD-1/LAG-3 mediated resistance. © The Author(s) 2024.

Description

Keywords

Cancer Immunotherapy, CBL Ubiquitin Ligases, LAG-3, PD-1, T-cell Dysfunctionality

Department

Ciencias de la Salud / Osasun Zientziak

Faculty/School

Degree

Doctorate program

item.page.cita

Chocarro, L., Blanco, E., Fernandez-Rubio, L., Garnica, M., Zuazo, M., Garcia, M. J., Bocanegra, A., Echaide, M., Johnston, C., Edwards, C. J., Legg, J., Pierce, A. J., Arasanz, H., Fernandez-Hinojal, G., Vera, R., Ausin, K., Santamaria, E., Fernandez-Irigoyen, J., Kochan, G., Escors, D. (2024). PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets. EMBO Molecular Medicine, 16(8), 1791-1816. https://doi.org/10.1038/s44321-024-00098-y.

item.page.rights

© The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License.

Los documentos de Academica-e están protegidos por derechos de autor con todos los derechos reservados, a no ser que se indique lo contrario.